FYB Stock Overview
A biotechnology company, develops biosimilar drugs in Germany and Switzerland. More details
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 5/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Formycon AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €46.45 |
| 52 Week High | €67.70 |
| 52 Week Low | €37.75 |
| Beta | 0.84 |
| 11 Month Change | -8.20% |
| 3 Month Change | -11.19% |
| 1 Year Change | -23.98% |
| 33 Year Change | -1.07% |
| 5 Year Change | 49.84% |
| Change since IPO | 410.44% |
Recent News & Updates
Recent updates
Shareholder Returns
| FYB | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -0.6% | -0.7% | -0.02% |
| 1Y | -24.0% | -17.2% | 8.2% |
Return vs Industry: FYB underperformed the German Biotechs industry which returned -17.2% over the past year.
Return vs Market: FYB underperformed the German Market which returned 8.2% over the past year.
Price Volatility
| FYB volatility | |
|---|---|
| FYB Average Weekly Movement | 4.6% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: FYB has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: FYB's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 239 | Stefan Glombitza | www.formycon.com |
Formycon AG, a biotechnology company, develops biosimilar drugs in Germany and Switzerland. It provides FYB201, a biosimilar candidate for Lucentis, an ophthalmic drug used in the treatment of neovascular age-related macular degeneration and other serious retinal diseases, including diabetic macular edema, choroidal neovascularization, proliferative diabetic retinopathy, and macular edema under the Ranivisio, Ongavia, Cimerli, Ranpoto, Uptera, and Ravegza names. The company’s pipeline includes FYB202, a biosimilar candidate for Stelara used in the treatment of Psoriasis, Crohn’s disease, and ulcerative colitis which has completed the Phase III clinical trial; and FYB203, a biosimilar candidate for Eylea that treats ophthalmology related diseases, including neovascular age-related macular degeneration that has completed Phase III clinical trials.
Formycon AG Fundamentals Summary
| FYB fundamental statistics | |
|---|---|
| Market cap | €827.23m |
| Earnings (TTM) | €63.90m |
| Revenue (TTM) | €60.80m |
12.9x
P/E Ratio13.6x
P/S RatioIs FYB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FYB income statement (TTM) | |
|---|---|
| Revenue | €60.80m |
| Cost of Revenue | €53.22m |
| Gross Profit | €7.58m |
| Other Expenses | -€56.32m |
| Earnings | €63.90m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 28, 2024
| Earnings per share (EPS) | 3.62 |
| Gross Margin | 12.46% |
| Net Profit Margin | 105.09% |
| Debt/Equity Ratio | 0% |
How did FYB perform over the long term?
See historical performance and comparison